Disease | collagen disease |
Phenotype | C0034735|raynaud\'s phenomenon |
Sentences | 9 |
PubMedID- 26421308 | When used together, autoantibodies and capillaroscopic findings are generally accepted as a powerful diagnostic tool for detecting emerging connective tissue diseases (ctds) in patients with raynaud's phenomenon [3–7]. |
PubMedID- 22883334 | Objective: to observe nailfold capillary changes in a cohort of connective tissue disease (ctd) with raynaud's phenomenon (rp) and to explore the diagnostic value of nailfold video-capillaroscopy (nvc) in systemic sclerosis (ssc). |
PubMedID- 26016221 | Secondary raynaud's phenomenon is common with rheumatic diseases (systemic sclerosis, systemic lupus erythematosus, primary sjogren's syndrome, mixed connective tissue disease, etc.), occlusive vascular diseases, hematologic disorders, use of vibrating tools and use of some medications, and rarely with malignancy. |
PubMedID- 24517537 | Objectives: nailfold capillaroscopy (nc) and laboratory tests for antinuclear antibodies (ana) are routinely used in parallel for detection of emerging connective tissue disease (ctd) in patients with raynaud's phenomenon (rp). |
PubMedID- 24016612 | Clinical applicability of quantitative nailfold capillaroscopy in differential diagnosis of connective tissue diseases with raynaud's phenomenon. |
PubMedID- 21875018 | Capillaroscopy as a prognostic tool for the development of connective tissue disease in patients with raynaud's phenomenon. |
PubMedID- 24910968 | Nailfold capillaroscopy is also commercially available, with significant published literature that supports its use for detecting microangiopathy secondary to specific connective tissue diseases in patients with raynaud's phenomenon. |
PubMedID- 22077618 | Sarpogrelate hydrochloride (sarpogrelate) is a selective 5-ht(2a) antagonist and was supposed to be effective for raynaud's phenomenon with collagen disease. |
PubMedID- 20194444 | Thumb involvement in raynaud's phenomenon as an indicator of underlying connective tissue disease. |
Page: 1